Lead Product(s): Alogliptin
Therapeutic Area: Endocrinology Product Name: Nesina
Highest Development Status: Approved Product Type: Small molecule
Deal Size: $278.0 million Upfront Cash: $266.0 million
Deal Type: Divestment June 11, 2020
The portfolio to be divested to Celltrion includes a variety of OTC products and pharmaceutical products such as Nesina® and Edarbi® and Products in a variety of indications.